SCHEMBL3083887

SCHEMBL3083887

COc1ccc(-c2ccc(S(=O)(=O)NC(C)c3cnn[nH]3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 16/20 0.51
MMP13 P45452 11/20 0.51
MMP9 P14780 9/20 0.51
MMP3 P08254 8/20 0.51
MMP8 P22894 7/20 0.51
MMP1 P03956 7/20 0.51
MMP7 P09237 6/20 0.51
CA12 O43570 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
MMP14 P50281 2/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
LMNA P02545 1/20 0.44
ADAMTS4 O75173 1/20 0.43
CNR1 P21554 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3087754 0.88 MMP2 (0.52) MMP2MMP13MMP9MMP3MMP8
SCHEMBL3087707 0.83 MMP2 (0.47) MMP2MMP13MMP9MMP3MMP8
SCHEMBL3090320 0.74 ALDH1A1 (0.51) LMNA
SCHEMBL29259797 0.72 CA1 (0.68) MMP2MMP13MMP9MMP3MMP8
SCHEMBL5198657 0.70 LMNA (0.68) MMP2MMP13MMP9MMP3MMP8
SCHEMBL3090529 0.70 MMP2 (0.59) MMP2MMP13MMP9MMP3MMP8
SCHEMBL3078516 0.69 MMP3 (0.45) MMP2MMP13MMP9MMP3MMP8
SCHEMBL11065834 0.69 CNR1 (0.70) MMP2MMP13MMP9MMP3MMP8
SCHEMBL28354122 0.68 CNR1 (0.77) MMP2MMP13MMP9MMP3MMP8
SCHEMBL7761532 0.68 MMP2 (1.00) MMP2MMP13MMP9MMP3MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-09-16 US claimed
WO-2008024784-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2008-02-28 WO claimed
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-09-16 US disclosed
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-09-16 US disclosed
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-09-16 US disclosed
WO-2008024784-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS MMP3, MMP11, MMP13 MMP2 14/4885MMP13 3/4885MMP9 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.